Orphazyme A S (CE) (OZYMF) News

After RS what is AS?

OZYMF: effective Dec. 6,2023 a one for 1,000 reverse split;

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Not double down?

Now what

https://www.clinicaltrialsarena.com/comment/orphazymes-arimoclomol-expected-to-be-used-with-zavesca-after-likely-fda-approval-in-niemann-pick-disease-type-c/

https://www.fda.gov/news-events/press-announcements/fda-awards-18-grants-stimulate-product-development-rare-diseases

https://www.fda.gov/news-events/press-announcements/fda-awards-18-grants-stimulate-product-development-rare-diseases

Nice!

https://finviz.com/quote.ashx?t=ORPH

Nice pop looks like all the low float small caps are moving finally $ORPH

Holding ...

Can $ORPH pull a $BBI* I think so. Game time starting today.

Next calls to start running hot like $MMA* and $MRI* is this gem $ORPH

GM, why did this go down? Anyone

Looks like time to add some here

$ORPH: Looks like time to LOAD again here......



Sub $6 while you can.



HIGHEST SHORT interest BUILDING again


Top Mention on REDDIT


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164323534



GO $ORPH

ORPH just showed up on the hard to borrow list as it did back in June before the spike to $75. A lot of volume the last 2 days tells me we may be looking at another squeeze. Getting more expensive to borrow as well. https://iborrowdesk.com/report/ORPH

Here we go again !

Looks like she’s heading back down again unfortunately smh

ORPH chart

I saw that it’s huge news Imo!!! $ORPH

Orphazyme US Patent & Trademark Office Abstract For Co.'s 'HEAT SHOCK PROTEINS AND CHOLESTEROL HOMEOSTASIS'
Benzinga Newsdesk , Benzinga Staff Writer FOLLOW
June 24, 2021 10:16am

Exactly!!! Shorts are trying desperately to cover today for that reason $ORPH

possibly worse case by tomorrow. AGreed!

Slow and steady grind upwards to the $10 break now $ORPH

Grabbed a good chunk today think we break $10 by midday $ORPH

Yes, this company has a future too. It's just not the pump everyone wanted to $30+

The fact they are still holding 5% probably came across as being somewhat positive, after the most recent news,can't find info on out standing and float size, but that amount is got to be worth many millions, just having one percent, could buy one really big house on the beach, and many fancy cars, and the average Joe would be able sit on their butt for the rest of their life.

No , next push IMO

As in today?

No but maybe cross $10 again near term

Is this gonna do a repeat of the epic June 10th?

In iHUB news now about Goldman

Yeah, that started it all. I think sometimes the big guys pump to get their buddies out.

who knows this whole marfket is crazy https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164321615&txt2find=orph

yeah crazy how this works. I have no clue how it happens this way.

WOW $9's already


ORPH

Not sure how a share reduction is good news but perhaps the fact they are keeping shares?

https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=3926403&lang=en-GB&companycode=dk-orpha&v=ticker

please post any...


Message in reply to:

Goldman news! HMM?

Fuck me … I sold Monday for a small lost … I knew it had a pop in it, why didn’t I listen to my gut and sit on my hands is beyond me

Goldman news! HMM?

ORPH POP

buy all you can now RLTR,was $1.03,.13 cents now,1000%% easy runner

And. Make sure sell what you had. Take a loss. Don’t ever come back. After FDC thumbs down this company will never be a winner. Denmark? Never. No prolific possibilities. POS times 10

You’re pretty late with this....it was determined to be a POS last week. Thank you Captain Hindsight

Is Orphazyme a Winner in the Biotech Industry?

ORPH – Shares of Denmark-based biopharmaceutical company Orphazyme’s (ORPH) experienced extreme volatility this month due to the actions of retail traders that were triggered by discussions about the stock on social media platforms such as Reddit. After hitting its $4.75 all-time low on June 2, this meme stock soared to hit its $77.77 all-time high on June 10. The stock has gained 28.6% over the past month, but let’s find out if it has upside remaining given the FDA’s rejection of its Niemann-Pick treatment.

Manisha ChatterjeeBy Manisha Chatterjee
Jun 21, 2021


Headquartered in Copenhagen, Denmark, shares of relatively unknown biopharmaceutical company Orphazyme A/S (ORPH - Get Rating) soared to hit their $77.77 all-time high on June 10, 2021, on investors’ anticipation of FDA approval of the company’s lead pipeline candidate arimoclomol for the treatment for Niemann-Pick disease type C (NPC).

The rally was primarily a result of retail traders’ investments that were driven by enthusiasm surrounding the stock on social media platforms such as Reddit. However, the company issued a notice on June 11 that the surge in its stock price was not related to any material change in its clinical development programs or financial condition and further warned its shareholders that they could lose a significant portion of their investments.

Indeed, the stock has declined 90.6% since hitting its all-time high, and by 40.8% over the past three months to close Friday’s trading session at $7.33. The decline can be attributed to ORPH’s announcement on June 18 that it failed to receive U.S. Food and Drug Administration’s (FDA) approval for the treatment of NPC. Furthermore, Johnson & Johnson’s (JNJ) Zavesca is already approved to treat other lysosomal disorders, which could pose a threat to ORPH. ORPH’s poor profitability is evident from its negative values for ROE and ROA. So, we think ORPH’s near-term prospects look bleak.

Here are the factors that we think could influence ORPH’s performance in the upcoming months:

FDA Rejection

ORPH announced on June 18 that it has received a Complete Response Letter (CRL) from the FDA following its review of its new drug application for arimoclomol, which is a heat shock protein amplifier intended for the treatment of NPC. The FDA said that it would need additional qualitative and quantitative data. ORARIALS-01 pivotal trial of arimoclomol in amyotrophic lateral sclerosis (ALS) and its phase 2/3 trial evaluating arimoclomol for the treatment of inclusion body myositis (IBM) also did not meet its primary and secondary endpoints.

Consequently, the company lowered its guidance for its fiscal 2021. ORPH now anticipates its operating loss to come in between DKK 670 million ($106.85 million) and DKK 700 million ($111.63 million) in its fiscal year 2021. The loss was previously anticipated to be in the range of DKK 100 million ($15.95 million) and DKK 150 million ($23.92 million). Its cash position at year-end 2021 is expected to be roughly DKK 50 million ($7.97 million) compared to DKK 350 million ($55.82 million), which was expected earlier.

Ongoing Investigation

Several law firms, including Pomerantz LLP and Bronstein, Gewirtz & Grossman, LLC, have launched investigations against ORPH to identify whether the company and certain of its officers and/or directors are engaged in securities fraud or other unlawful business practices. ORPH completed its IPO in September 2020, and on May 7, 2021, it issued a press release that ORARIALS-01 pivotal trial of arimoclomol in ALS did not meet its primary and secondary endpoints to show benefit in people living with ALS.

Lofty Valuation Not in Sync with Financials

In terms of forward EV/S, ORPH’s 13.70x is 99.1% higher than the 6.88x industry average. The stock’s 20.60x forward P/S is also higher than the 7.71x industry average. However, ORPH’s operating loss increased 81.1% year-over-year to DKK 608.53 million ($97.05 million) for the fiscal year ended December 31, 2020. Its net loss for the year increased 87.6% year-over-year to DKK 633.25 million ($100.99 million).

Consensus Price Target Indicates Downside

ORPH is currently trading at $7.33 and Wall Street analysts expect the stock to hit $5 in the near term, which indicates a potential 31.8% decline.

Bottom Line

ORPH’s stock is currently trading 90.6% below its all-time high and it is expected to decline further given the U.S. FDA’s rejection of its lead candidate arimoclomol. Analysts expect its EPS to remain negative in fiscal 2021 and 2022. So, we think the stock is best avoided now.

Yes crazy ! Didn’t get
Burnt bad but we all believed it would pass and crappy they told them last minute. The hedge fund getting out just a week ago should have flagged me

Yeah this one hurt didn’t demolish me but seems I shoulda taken the profit and run

Agreed ! Tired of big pharma stealing our money and good drugs

They got screwed by a corrupt fda Johnson and Johnson can be
Allowed to but out a shit vaccine but shut down years of proven research with better results obviously some other big Pharms company made sure they didn’t get approval